GoodRx (NASDAQ:GDRX) Hits New 52-Week Low at $5.56

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Rating) hit a new 52-week low on Wednesday . The company traded as low as $5.56 and last traded at $5.59, with a volume of 38409 shares. The stock had previously closed at $5.71.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on GDRX shares. Royal Bank of Canada upped their target price on GoodRx from $6.50 to $11.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 9th. The Goldman Sachs Group increased their price objective on GoodRx from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Tuesday, August 9th. Bank of America initiated coverage on GoodRx in a research report on Monday, June 6th. They set a “buy” rating and a $11.00 price objective on the stock. Credit Suisse Group increased their target price on GoodRx from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, August 9th. Finally, Robert W. Baird dropped their target price on GoodRx from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $15.08.

GoodRx Trading Down 3.7 %

The company has a debt-to-equity ratio of 0.80, a current ratio of 11.23 and a quick ratio of 11.23. The company has a fifty day moving average price of $6.44 and a 200-day moving average price of $9.92.

GoodRx (NASDAQ:GDRXGet Rating) last issued its earnings results on Monday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. GoodRx had a positive return on equity of 2.97% and a negative net margin of 5.86%. The firm had revenue of $191.80 million for the quarter, compared to analysts’ expectations of $184.71 million. During the same period in the previous year, the firm posted $0.08 earnings per share. The business’s revenue was up 8.6% compared to the same quarter last year. As a group, analysts predict that GoodRx Holdings, Inc. will post 0.02 EPS for the current year.

Institutional Investors Weigh In On GoodRx

Several large investors have recently added to or reduced their stakes in GDRX. Qube Research & Technologies Ltd bought a new stake in GoodRx during the fourth quarter worth approximately $706,000. Bank of Montreal Can increased its stake in GoodRx by 108.0% during the fourth quarter. Bank of Montreal Can now owns 187,216 shares of the company’s stock worth $6,208,000 after acquiring an additional 97,221 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in GoodRx by 5.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 8,563 shares of the company’s stock worth $279,000 after acquiring an additional 421 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in GoodRx by 62.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,939,071 shares of the company’s stock worth $63,369,000 after acquiring an additional 742,906 shares during the last quarter. Finally, Ardmore Road Asset Management LP bought a new stake in GoodRx during the fourth quarter worth approximately $1,634,000. 39.16% of the stock is owned by institutional investors.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.